Project Grant R01GM157516
- The National Institute of General Medical Sciences awarded Sanford Research $456,500 on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to study the regulation of nucleocytoplasmic compartmentalization and nuclear envelope function. The research focuses on the nuclear envelope's role in supporting critical cellular functions including genome protection and organization, segregation of transcription and translation, and cell signaling. The project will...
- The National Institute of General Medical Sciences awarded the University of South Florida $474,102 on June 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to conduct synthetic biology and genome engineering of polyketide natural products, develop bioactive metabolites from Antarctic marine invertebrates and deep-sea organisms, synthesize chemical analogs to modulate toxicity and enhance drug-like properties, and advance compound development initiatives...
- The National Institute of General Medical Sciences awarded the University of North Dakota $112,084 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to study mentorship structures that shape biomedical researcher career trajectories and long-term persistence in independent research. The recipient will integrate longitudinal dissertation records, publication data, and collaboration histories to reconstruct advisor-student relationships spanning...
- The National Institute of General Medical Sciences awarded The Salk Institute for Biological Studies $515,625 on June 12, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate fundamental mechanisms of cytoskeletal dynamics and transport, with focus on how connector proteins link molecular motors to cellular cargo and facilitate transport along microtubule tracks. The research examines two primary areas: the role of spectraplakin proteins, which link...
- This $350,000 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859) to Black Hills State University in Spearfish, South Dakota. The grant supports the development of genetically encoded sensors to quantify unconjugated NEDD8, a post-translational modifier that regulates cullin-ring E3 ligases, which are being explored as drug targets for solid-tumor cancers. The research aims to...
- The National Institute of Biomedical Imaging and Bioengineering awarded $2.799 million to the University of South Dakota on June 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop engineered mesenchymal stem cells (MSCs) with programmable cellular theranostic capabilities through synthetic biology approaches. The project addresses poor survival and reduced regenerative capacity of MSCs in hostile tissue...
- The National Institute of General Medical Sciences awarded the University of Massachusetts $2.35 million on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to investigate non-specific electrostatic interactions of biological macromolecules in physiological and pathological processes. The project examines how highly charged polycationic and polyanionic biomacromolecules — including heparin, neutrophil extracellular traps, and other polymeric species —...
- The National Heart Lung and Blood Institute awarded South Dakota State University $452,869 on April 20, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837, Project Grant R01HL175395) to investigate lymphatic valve dysfunction and lymphedema pathogenesis through study of intraflagellar transport proteins and primary cilia regulation in lymphatic endothelial cells. The funded research examines how intraflagellar transport (IFT) proteins, specifically IFT74 and IFT20, regulate...
- The National Institute of General Medical Sciences awarded the University of South Carolina $320,914 on August 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to support research on the evolution of facial amphiphilicity toward alternating copolymers as antimicrobial biomaterials. The funded research investigates the design of synthetic macromolecules—specifically alternating copolymers and synthetic polypeptides—that replicate facial amphiphilicity (the...
- The National Institute of General Medical Sciences awarded the University of Utah $885,637 in project grant funding on March 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859). The University of Utah, through its Office of Sponsored Projects Division, will conduct a five-year investigation into the molecular and metabolic adaptations that enable apicomplexan parasites—particularly Plasmodium species that cause malaria—to survive and replicate within host cells....
The National Institute of General Medical Sciences awarded South Dakota State University $304,952 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to elucidate mechanisms of macropinosome formation, stabilization, and trafficking. The research investigates how macropinocytosis—the non-specific, receptor-independent internalization of solutes through large endocytic structures—operates in macrophages, T cells, and cancer cells. The project tests the hypothesis that UVRAG in cooperation with VPS34-II complex provides positive regulation of macropinocytosis by facilitating recruitment of effectors mediating stabilization, maturation, and trafficking, while PAK2 provides negative regulation. The study pursues three specific aims: determining how UVRAG and VPS34-II stabilize macropinosomes following formation and facilitate transit through cellular compartments; characterizing how PAK2 negatively regulates macropinocytosis and the role of RAC1 GTP-GDP cycling; and identifying novel mediators and cellular mechanisms using CRISPR/Cas9 screens and phosphoproteome analysis. Performance occurs in South Dakota, with a period of performance through April 30, 2030. This is a Project Grant, the standard NIH mechanism for investigator-initiated biomedical research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $305.0k | 8/13/26 |